Search results for "Read through"
showing 4 items of 4 documents
Identification and validation of novel molecules obtained by integrated computational and experimental approaches for the read-through of PTCs in CF …
2015
U.I.R.D.A. – Unbuilt Italian Rationalism Digital Archive
2018
For twenty years, the architecture of Italian rationalism through the digital modelling has been investigated. Very often, the production of a model and the consequent representation of tridimensional views, in many case studies, as outcome of the research on architecture have been considered. Actually, the digital model, intended as a critical tool, has to be conceived as a ‘starting point' for graphic analysis of architecture and not as the outcome. Indeed, it is associated to other graphics, sometimes not ‘deducted' from the model, useful for the understanding/translation of architecture. The construction of the model is not the construction of a simple image, operation, which is often c…
Rescuing CFTR Protein Function: 1,3,4-oxadiazoles versus 1,2,4-oxadiazoles as readthrough inducing drugs
In Cystic fibrosis (CF) disease nonsense mutations in the CFTR gene cause the absence of the CFTR protein expression and a more severe form of the disease. About 10% of patient affected by CF show a nonsense mutation. A potential treatment of this alteration is to promote translational readthrough of premature termination codons (PTCs) by translational readthrough inducing drugs such as Ataluren (1). We reported a rationale for Ataluren promoted readthrough of PTCs by computational approach and GFP-reporter cell-based assay (2) and the observed enhancement of readthrough activity by some Ataluren derivatives (3, 4). In this context we aimed to compare the 1,2,4-oxadiazole core of Ataluren w…
OXADIAZOLE DERIVATIVES FOR THE TREATMENT OF GENETIC DISEASES DUE TO NONSENSE MUTATIONS
2018
Are disclosed oxadiazole derivatives, their use as medicaments and in particular for the treatment of diseases associated with the presence of a nonsense mutation in the gene or a premature stop codon in the mRNA, pharmaceutical formulation comprising said oxadiazole derivatives and prodrug or mixture thereof and the methods for the preparation of said Oxadiazole derivatives.